{"id":2280,"date":"2026-06-11T03:00:00","date_gmt":"2026-06-11T06:00:00","guid":{"rendered":"https:\/\/sevenresiduosaude.com.br\/blog\/?p=2280"},"modified":"2026-06-11T03:00:00","modified_gmt":"2026-06-11T06:00:00","slug":"rss-clinica-medicina-gastroenterologia-dii-crohn-uc-ustekinumab-vedolizumab-jak-crc-screening","status":"publish","type":"post","link":"https:\/\/sevenresiduosaude.com.br\/blog\/rss-clinica-medicina-gastroenterologia-dii-crohn-uc-ustekinumab-vedolizumab-jak-crc-screening\/","title":{"rendered":"RSS gastro: DII, Crohn, UC, biol\u00f3g, JAK"},"content":{"rendered":"

A regula\u00e7\u00e3o brasileira de RSS \u00e9 frequentemente subaproveitada por gestores de cl\u00ednicas de gastroenterologia que reduzem RSS a descarte de c\u00e1psula endosc\u00f3pica e gaze<\/strong>. Em 2026, h\u00e1 um cen\u00e1rio desafiador \u2014 cl\u00ednicas de gastroenterologia<\/strong> + DII doen\u00e7a inflamat\u00f3ria intestinal Crohn CD+RCU UC ulcerative colitis+IBD-U indeterminada<\/strong> + anti-TNF infliximab Remicade+adalimumab Humira+golimumab Simponi+certolizumab Cimzia<\/strong> + anti-\u03b14\u03b27 vedolizumab Entyvio<\/strong> + anti-IL-12\/23 ustekinumab Stelara+anti-IL-23 risankizumab Skyrizi+mirikizumab Omvoh<\/strong> + JAK inhibitors tofacitinib Xeljanz+upadacitinib Rinvoq+filgotinib Jyseleca<\/strong> + S1P modulator ozanimod Zeposia+etrasimod Velsipity<\/strong> + DRGE+H. pylori erradica\u00e7\u00e3o+\u00falcera p\u00e9ptica+cel\u00edaca+hepatite virais+esteatose hep\u00e1tica NAFLD\/MASH+resmetirom Rezdiffra+CRC screening colonoscopia+cologuard+Galleri MCED<\/strong> geram fluxos heterog\u00eaneos de RSS Grupo A1 (DII Crohn+UC + adenoCa colorretal screening + esof\u00e1gico Barrett + est\u00f4mago H. pylori + bi\u00f3psia colonoscopia m\u00faltipla + sangue venoso ASCA+ANCA+anti-tTG+IgA+H. pylori urease+sorologia hepatite+ferritina+vit B12+\u00e1cido f\u00f3lico) + Grupo A2 (escarro tuberculose latente IGRA pr\u00e9-anti-TNF + lavado bronco-alveolar) + Grupo B (anti-TNF infliximab+adalimumab+golimumab+certolizumab + vedolizumab Entyvio + ustekinumab Stelara+risankizumab Skyrizi+mirikizumab Omvoh + JAK tofacitinib+upadacitinib+filgotinib + S1P ozanimod+etrasimod + 5-ASA mesalazina Asacol+Pentasa+Salofalk + corticoide budesonida Entocort+Uceris+prednisona + AZT azatioprina+6-MP+MTX + IBP omeprazol+pantoprazol+esomeprazol+rabeprazol+lansoprazol+vonoprazan Voquezna PCAB + DAA hepatite C Sovaldi+Harvoni+Mavyret+Epclusa+Vosevi + tenofovir HBV + resmetirom Rezdiffra MASH\/NASH Madrigal Lista B\/C5) + Grupo E (perfuro Vacutainer + agulha core bi\u00f3psia hep\u00e1tica Tru-Cut + colonosc\u00f3pio Olympus EVIS X1+Pentax+Fujifilm + ESD endoscopic submucosal dissection IT-knife + EUS-FNA endoscopic ultrasound + ERCP+SpyGlass cholangioscopy).<\/p>\n

Para o gestor que opera ou planeja cl\u00ednica de gastroenterologia, \u00e9 fundamental dimensionar RSS espec\u00edfico desde o in\u00edcio.<\/p>\n

Os 5 fluxos gastroenterol\u00f3gicos<\/h2>\n

Em uma opera\u00e7\u00e3o de qualquer porte, o RSS gastro tem 5 fluxos.<\/p>\n\n\n\n\n\n\n\n\n\n
Fluxo<\/th>\nVolume<\/th>\nFrequ\u00eancia<\/th>\nParticularidade<\/th>\n<\/tr>\n<\/thead>\n
DII Crohn+UC+biol\u00f3gico<\/td>\n4-12 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nAnti-TNF+vedo+uste+JAK<\/td>\n<\/tr>\n
DRGE+H. pylori+\u00falcera<\/td>\n3-9 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nIBP+vonoprazan PCAB<\/td>\n<\/tr>\n
Hepatologia hep+MASH<\/td>\n2-6 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nDAA+resmetirom+TX<\/td>\n<\/tr>\n
CRC screening<\/td>\n2-6 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nColono+cologuard+MCED<\/td>\n<\/tr>\n
Endoscopia ESD+EUS<\/td>\n1,5-4,5 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nOlympus+ESD+ERCP<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

A soma t\u00edpica \u00e9 12,5-37,5 kg\/dia<\/strong> em cl\u00ednica gastro m\u00e9dia porte.<\/p>\n

DII Crohn + UC + anti-TNF + vedolizumab + ustekinumab + JAK + S1P modulator: o est\u00e1gio inflamat\u00f3rio<\/h2>\n

A primeira camada \u00e9 DII. Padr\u00e3o setorial inclui (a) Crohn diagn\u00f3stico<\/strong> com Montreal classification A1<17\/A2 17-40\/A3>40 + L1 ileal+L2 c\u00f3lon+L3 ileocol\u00f4nica+L4 GI superior + B1 inflamat\u00f3rio+B2 estenosante+B3 fistulizante + ASCA+\/ANCA-+calprotectina fecal+ileocolonoscopia+bi\u00f3psia+RM enterografia; (b) UC ulcerative colitis<\/strong> com Montreal extension E1 proctite+E2 distal+E3 pancolite + Mayo score 0-12 + endosc\u00f3pico Mayo subscore 0-3 + UCEIS Ulcerative Colitis Endoscopic Index of Severity; (c) anti-TNF biological 1L moderada-grave<\/strong> com infliximab Remicade Janssen IV+Inflectra biossimilar + adalimumab Humira AbbVie SC q2w + Hyrimoz Sandoz biossimilar + golimumab Simponi Janssen + certolizumab pegol Cimzia UCB; (d) anti-\u03b14\u03b27 integrin vedolizumab Entyvio Takeda<\/strong> GEMINI 1\/2\/3 IV q8w + manuten\u00e7\u00e3o SC + gut-selective; anti-IL-12\/23 ustekinumab Stelara Janssen<\/strong> UNITI\/IM-UNITI + 6 mg\/kg IV+90 mg SC q8w + risankizumab Skyrizi AbbVie ADVANCE\/MOTIVATE+INSPIRE\/COMMAND + mirikizumab Omvoh Lilly LUCENT-1\/2 UC; (e) JAK inhibitors 2L<\/strong> tofacitinib Xeljanz Pfizer JAK1\/3 OCTAVE-1\/2\/SUSTAIN UC + upadacitinib Rinvoq AbbVie JAK1 U-ACHIEVE+U-EXCEL+U-ENDURE + filgotinib Jyseleca Galapagos JAK1 SELECTION; S1P modulator<\/strong> ozanimod Zeposia BMS True North UC + etrasimod Velsipity Pfizer ELEVATE UC.<\/p>\n

Cl\u00ednica com DII madura escala remiss\u00e3o cl\u00ednica+endosc\u00f3pica STRIDE-II<\/strong> + previne f\u00edstula+cirurgia 30-50%<\/strong> + otimiza T2T treat-to-target STRIDE-II<\/strong>. Como discutimos no post sobre reumato<\/a>, DII \u00e9 base.<\/p>\n

DRGE + H. pylori + \u00falcera + IBP + vonoprazan + hepatologia DAA + MASH resmetirom: o est\u00e1gio funcional+hepatol\u00f3gico<\/h2>\n

A segunda camada \u00e9 DRGE+hepatologia. Padr\u00e3o setorial inclui (a) DRGE doen\u00e7a refluxo gastroesof\u00e1gico<\/strong> com IBP omeprazol+pantoprazol+esomeprazol+rabeprazol+lansoprazol + vonoprazan Voquezna Phathom PCAB potassium-competitive acid blocker PHALCON-EE GERD + endoscopia Los Angeles A-D + Stretta+TIF transoral incisionless fundoplication; (b) H. pylori erradica\u00e7\u00e3o<\/strong> com tripla amoxicilina+claritromicina+IBP + qu\u00e1drupla bismuto+tetraciclina+metronidazol+IBP + vonoprazan-baseado triplo VONOPRAZAN-amoxi-claritro pCONVINCE; (c) \u00falcera p\u00e9ptica + complica\u00e7\u00e3o<\/strong> com IBP cura 80-95% + ressangramento Forrest Ia-III + adrenalina+clip+termo+APC argon plasma coagulation + Hemospray endoscopic; (d) hepatologia hep B\/C<\/strong> com HBV tenofovir TDF Viread+entecavir Baraclude + HCV DAA Sofosbuvir Sovaldi+Ledipasvir Harvoni+Glecaprevir+Pibrentasvir Mavyret+Velpatasvir Epclusa+Vosevi SVR-12 >95% + transplante hep\u00e1tico Mayo; (e) MASH\/NASH non-alcoholic steatohepatitis<\/strong> com fibrose F0-F4 + FibroScan + MRE magnetic resonance elastography + resmetirom Rezdiffra Madrigal THR-\u03b2 agonist MAESTRO-NASH FDA 2024 1L + semaglutida ESSENCE + GLP-1 dual + GIP triple + lanifibranor PPAR pan-agonist NATIVE Lista B\/C5.<\/p>\n

Cl\u00ednica com DRGE+hepatologia+MASH madura escala HCV SVR>95% DAA<\/strong> + escala vonoprazan PCAB GERD superior IBP<\/strong> + escala resmetirom MASH MAESTRO-NASH FDA 2024 1L<\/strong>. Conex\u00e3o com Lista C5<\/a>.<\/p>\n

CRC screening colonoscopia + Cologuard + Galleri MCED + endoscopia ESD+EUS+ERCP+SpyGlass: o est\u00e1gio diagn\u00f3stico avan\u00e7ado<\/h2>\n

A terceira camada \u00e9 screening+endoscopia. Padr\u00e3o setorial inclui (a) CRC screening<\/strong> com colonoscopia gold standard 50-75 anos q10y + sigmoidoscopia flex\u00edvel + sigmoidoscopia+FIT + Cologuard Exact Sciences DNA fecal stool DNA Cologuard 2 SDM-COLOR\/Bluestar Genomics+ColoGuard 2.0; (b) MCED multi-cancer early detection<\/strong> com Galleri Grail Illumina ctDNA methylation 50+ cancers PATHFINDER+SUMMIT + ColoSense+Freenome + miRNA Roche; (c) colonoscopia endoscopia avan\u00e7ada<\/strong> com Olympus EVIS X1+CV-1500 + Pentax i20c+i30c + Fujifilm EI-740+CMOS + chromoendoscopia \u00edndigo carmim + NBI Narrow Band Imaging + AI-assisted polyp detection CADe Medtronic GI Genius+Olympus EndoBRAIN; (d) ESD endoscopic submucosal dissection<\/strong> com Olympus EndoCut Q+Erbe VIO 300D + IT-knife 1+2+nano + Hook-knife + Triangle-tip-knife + Dual-knife J + ressec\u00e7\u00e3o en bloc T1a M1-M3; (e) EUS-FNA endoscopic ultrasound + ERCP + SpyGlass<\/strong> com Olympus GF-UCT260+Pentax FG-38UX + EUS-FNA core 19G+22G+25G ProCore+Acquire + ERCP+sphincterotomy+stenting+SpyGlass DS Boston Scientific cholangioscopy direct visualization+SpyBite bi\u00f3psia.<\/p>\n

Cl\u00ednica com CRC screening+endoscopia avan\u00e7ada madura escala detec\u00e7\u00e3o precoce ADR Adenoma Detection Rate >25%<\/strong> + escala AI-assisted polyp +14% sensitivity<\/strong> + escala MCED Galleri 50+ cancers Stage I\/II detection<\/strong>. Conex\u00e3o com colorretal direito<\/a>.<\/p>\n

Tr\u00eas perfis de RSS por capacidade gastro<\/h2>\n

Cl\u00ednica gastro b\u00e1sica.<\/strong> 2 fluxos. Custo mensal R$ 12.000-32.000<\/strong> mas perda de DII biol\u00f3gico+JAK+CRC screening+MCED.<\/p>\n

Cl\u00ednica gastro m\u00e9dia.<\/strong> 3 fluxos. Custo mensal R$ 24.000-58.000<\/strong>, captura DII+DRGE+hepatologia.<\/p>\n

Cl\u00ednica gastro completa 5 fluxos.<\/strong> DII+DRGE+hepatologia+CRC+endoscopia + integra\u00e7\u00e3o com servi\u00e7os hospitalares<\/a>. Custo mensal R$ 45.000-105.000<\/strong>, efic\u00e1cia 95%, ROI 800-2.500% via captura gastroenterol\u00f3gica + DII biol\u00f3gico+JAK+S1P + CRC screening+MCED+ESD R0 90+%.<\/p>\n

Os tr\u00eas erros que aparecem em gastro<\/h2>\n

O primeiro \u00e9 a subdimensionamento DII biol\u00f3gico+JAK+S1P Lista C5<\/strong>. Sem segrega\u00e7\u00e3o infliximab+adalimumab+vedolizumab+ustekinumab+risankizumab+mirikizumab+tofacitinib+upadacitinib+filgotinib+ozanimod+etrasimod + Lista C5 = n\u00e3o-conformidade ANVISA RDC 222 + risco contamina\u00e7\u00e3o cruzada + impacto financeiro biol\u00f3gico R$ 30-180k\/ano\/paciente.<\/p>\n

O segundo \u00e9 a mistura DII Crohn + UC + IBD-U<\/strong>. Confunde rastreabilidade Montreal + impossibilita Mayo+UCEIS+SES-CD scoring + risco indica\u00e7\u00e3o inadequada (vedolizumab vs ustekinumab vs JAK vs S1P).<\/p>\n

O terceiro \u00e9 a falta de protocolo TB latente IGRA pr\u00e9-anti-TNF<\/strong>. Sem QuantiFERON-TB Gold + IGRA + screening pr\u00e9-biol\u00f3gico + tratamento isoniazida latente = risco reativa\u00e7\u00e3o TB + zero rastreabilidade biosseguran\u00e7a + viola\u00e7\u00e3o NR-32.<\/p>\n

A regula\u00e7\u00e3o de RSS gastro no Brasil est\u00e1 em fase de moderniza\u00e7\u00e3o t\u00e9cnica acelerada com gastroenterologia especializada como prioridade. As institui\u00e7\u00f5es que estruturam fluxos completos desde o in\u00edcio \u2014 alinhadas com calend\u00e1rio 2026 de compliance<\/a> \u2014 atravessam o crescimento sem solavanco. Para gestores que precisam alinhar com gest\u00e3o paralela industrial, o portal Seven Res\u00edduos sobre servi\u00e7os completos<\/a> traz a perspectiva integrada. A SBP Sociedade Brasileira Hepatologia + FBG Federa\u00e7\u00e3o Brasileira Gastroenterologia<\/a> \u00e9 refer\u00eancia t\u00e9cnica nacional.<\/p>\n

Solicite cota\u00e7\u00e3o RSS gastro 5 fluxos completos<\/a><\/strong> \u2014 cap\u00edtulo dedicado a DII Crohn Montreal+UC Mayo+UCEIS+anti-TNF infliximab Remicade Janssen+adalimumab Humira AbbVie+golimumab Simponi+certolizumab Cimzia UCB+vedolizumab Entyvio Takeda GEMINI+ustekinumab Stelara Janssen UNITI+risankizumab Skyrizi AbbVie ADVANCE+mirikizumab Omvoh Lilly LUCENT+JAK tofacitinib Xeljanz Pfizer OCTAVE+upadacitinib Rinvoq AbbVie U-ACHIEVE+filgotinib Jyseleca Galapagos SELECTION+S1P ozanimod Zeposia BMS True North+etrasimod Velsipity Pfizer ELEVATE+5-ASA mesalazina+budesonida+AZT+6-MP+MTX Lista C5, DRGE IBP+vonoprazan Voquezna Phathom PCAB PHALCON-EE+H. pylori erradica\u00e7\u00e3o tripla+qu\u00e1drupla+vonoprazan-baseado pCONVINCE+\u00falcera Forrest+adrenalina+clip+APC+Hemospray, hepatologia HBV tenofovir+entecavir+HCV DAA Sovaldi+Harvoni+Mavyret+Epclusa+Vosevi SVR>95%+MASH FibroScan+MRE+resmetirom Rezdiffra Madrigal THR-\u03b2 MAESTRO-NASH FDA 2024+semaglutida ESSENCE+lanifibranor NATIVE, CRC screening colonoscopia+sigmoidoscopia+FIT+Cologuard Exact Sciences+ColoSense+Galleri Grail Illumina ctDNA methylation 50+ cancers PATHFINDER+SUMMIT+miRNA Roche+chromoendoscopia+NBI+AI-assisted Medtronic GI Genius+Olympus EndoBRAIN, endoscopia ESD Olympus EndoCut+Erbe VIO 300D+IT-knife+Hook-knife+Dual-knife+EUS-FNA Olympus GF-UCT260+ProCore+Acquire+ERCP+SpyGlass DS Boston Scientific+SpyBite.<\/p>\n","protected":false},"excerpt":{"rendered":"

RSS gastro: DII Crohn + UC + ustekinumab + JAK + screening. Veja.<\/p>\n","protected":false},"author":3,"featured_media":2279,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[3114,3113,1975,3115],"class_list":["post-2280","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-compliance-legislacao","tag-crohn","tag-dii","tag-gastroenterologia","tag-jak"],"_links":{"self":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2280","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/comments?post=2280"}],"version-history":[{"count":1,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2280\/revisions"}],"predecessor-version":[{"id":4363,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2280\/revisions\/4363"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media\/2279"}],"wp:attachment":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media?parent=2280"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/categories?post=2280"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/tags?post=2280"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}